Moderna surprised investors by reporting a third-quarter profit, largely due to effective cost-cutting measures and stronger-than-anticipated Covid vaccine sales. The company reported a net income of $13 million, or 3 cents per share, defying Wall Street’s expectations of a loss. In contrast, last year saw a significant net loss of $3.63 billion. Moderna’s revenue of $1.86 billion, driven predominantly by its Covid shot, surpassed expectations of $1.25 billion. The company is aiming for $1.1 billion in savings by 2027 to stabilize after the decline of its Covid business.
The quarter was also notable for including sales of Moderna’s new RSV vaccine, though these were below projections due to late approvals. However, the early U.S. approval of its latest Covid vaccine boosted its availability, which CEO Stéphane Bancel credited for improved sales, noting shipments doubled compared to 2023.
Despite the financial uptick, Moderna shares remained flat, and the company faces a 50% stock decrease this year amid a challenging vaccine market. Looking forward, Moderna is focusing on a rich pipeline of 45 development products, including shots for flu and personalized cancer vaccines, expecting to bring 10 to market within three years. Additionally, Moderna is revising its 2024 guidance to $3-$3.5 billion in sales, down from previous forecasts due to lower anticipated sales in Europe and fierce competition in the U.S. respiratory vaccine sector.
Operational cost reductions were significant, with third-quarter sales costs slashed by 77% from the previous year, along with a 36% drop in selling and administrative expenses. Other cost-saving measures include a decrease in research and development expenses. Despite these efforts, the company is still navigating its strategy post-Covid, heavily relying on its mRNA platform for future growth.
Original Story https://www.cnbc.com/2024/11/07/moderna-mrna-earnings-q3-2024.html
Category :
Tags:
